Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:23791182  

The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability.

Bryan King | Thomas Trimarchi | Linsey Reavie | Luyao Xu | Jasper Mullenders | Panagiotis Ntziachristos | Beatriz Aranda-Orgilles | Arianne Perez-Garcia | Junwei Shi | Christopher Vakoc | Peter Sandy | Steven S Shen | Adolfo Ferrando | Iannis Aifantis
Cell | 2013

Sequencing efforts led to the identification of somatic mutations that could affect the self-renewal and differentiation of cancer-initiating cells. One such recurrent mutation targets the binding pocket of the ubiquitin ligase Fbxw7. Missense FBXW7 mutations are prevalent in various tumors, including T cell acute lymphoblastic leukemia (T-ALL). To study the effects of such lesions, we generated animals carrying regulatable Fbxw7 mutant alleles. Here, we show that these mutations specifically bolster cancer-initiating cell activity in collaboration with Notch1 oncogenes but spare normal hematopoietic stem cell function. We were also able to show that FBXW7 mutations specifically affect the ubiquitylation and half-life of c-Myc protein, a key T-ALL oncogene. Using animals carrying c-Myc fusion alleles, we connected Fbxw7 function to c-Myc abundance and correlated c-Myc expression to leukemia-initiating activity. Finally, we demonstrated that small-molecule-mediated suppression of MYC activity leads to T-ALL remission, suggesting an effective therapeutic strategy.

Pubmed ID: 23791182

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R01 CA173636
  • Agency: NCI NIH HHS, United States
    Id: P30 CA016087
  • Agency: NCI NIH HHS, United States
    Id: R01 CA133379
  • Agency: NCI NIH HHS, United States
    Id: 5P30CA16087-31
  • Agency: NIGMS NIH HHS, United States
    Id: 1R01GM088847
  • Agency: NCI NIH HHS, United States
    Id: P30CA016087-30
  • Agency: NCI NIH HHS, United States
    Id: R01 CA149655
  • Agency: NCI NIH HHS, United States
    Id: R01 CA105129
  • Agency: NCI NIH HHS, United States
    Id: 5R01CA173636
  • Agency: NCI NIH HHS, United States
    Id: 1R01CA105129
  • Agency: Howard Hughes Medical Institute, United States
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM088847
  • Agency: NCI NIH HHS, United States
    Id: 1R01CA133379
  • Agency: NCI NIH HHS, United States
    Id: 1R01CA149655

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.